Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML

The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase. The current second generation of FDA-approved ABL tyrosine kinase inhibitors, da...

Descripción completa

Detalles Bibliográficos
Autores principales: Shieh, Marie P., Mitsuhashi, Masato, Lilly, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Expert Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140277/
https://www.ncbi.nlm.nih.gov/pubmed/21792346
http://dx.doi.org/10.4137/CMO.S6416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140277/
https://www.ncbi.nlm.nih.gov/pubmed/21792346
http://dx.doi.org/10.4137/CMO.S6416

Ejemplares similares